Drug intelligence / Profile preview

teprotide

Development stage
Discontinued
Lead developer
Bristol Myers Squibb
Modality
Peptides
Administration
Parenteral
01

Overview

Teprotide is a nonapeptide originally isolated from the venom of the Brazilian pit viper, *Bothrops jararaca*. It functions as an angiotensin-converting enzyme (ACE) inhibitor, blocking the conversion of angiotensin I to angiotensin II and potentiating the pharmacological actions of bradykinin. Although it demonstrated significant antihypertensive effects, its clinical utility was limited due to its peptide nature, requiring parenteral administration, its expense, and lack of oral activity. Teprotide played a crucial role as a lead compound in the rational design and development of the first orally active ACE inhibitors, such as captopril.

Other names
TepromideTeprotidumteprotidaNonapeptide-Converting Enzyme InhibitorEnzyme Inhibitor, Nonapeptide-ConvertingNonapeptide Converting Enzyme InhibitorL-pyroglutamyl-L-tryptophyl-L-prolyl-L-arginyl-L-prolyl-L-glutaminyl-L-isoleucyl-L-prolyl-L-proline
02

Targets

ACE (Angiotensin Converting Enzyme)

Beyond the preview

Go deeper on teprotide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on teprotide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call